Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Trim from Morgan Stanley

Merck & Co., Inc. (NYSE:MRK) had its price objective trimmed by Morgan Stanley from $179.00 to $177.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other analysts have also recently commented on the company. Royal Bank Of Canada cut Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and upped their price target for the stock from $142.00 to $150.00 in a research report on Thursday, August 20th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research report on Wednesday, August 12th. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Scotiabank increased their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a report on Tuesday, September 29th. Finally, HSBC raised their target price on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $151.32.

Merck & Co., Inc. Trading Up 2.2%

Shares of Merck & Co., Inc. stock opened at $145.52 on Wednesday. The company’s fifty day simple moving average is $143.90 and its 200-day simple moving average is $128.28. The stock has a market capitalization of $359.03 billion, a PE ratio of 116.42, a P/E/G ratio of 6.41 and a beta of 0.21. Merck & Co., Inc. has a 1-year low of $82.01 and a 1-year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Richard Deluca sold 11,699 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last three months. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $26,000. Bullseye Investment Management LLC bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Horizons Wealth Management purchased a new position in shares of Merck & Co., Inc. during the third quarter valued at about $30,000. Graney & King LLC grew its position in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC purchased a new position in shares of Merck & Co., Inc. during the second quarter valued at about $41,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.